CN-122005692-A - Traditional Chinese medicine composition particles and industrialized preparation method thereof

Abstract

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to traditional Chinese medicine composition particles and an industrialized preparation method thereof. The traditional Chinese medicine composition particles are prepared from, by mass, 580-640 parts of astragalus membranaceus, 350-400 parts of fried semen lepidii, 350-400 parts of ligusticum wallichii, 200-260 parts of cassia twig processed by glycerol, 200-260 parts of salted rhizoma alismatis, 130-160 parts of platycodon grandiflorum and 60-90 parts of Chinese dates. The technical scheme adopts a step-by-step extraction strategy that the ligusticum wallichii and the cassia twig are decocted firstly and then mixed with other medicinal materials, so that the medicinal effect is further ensured. The technical scheme can solve the technical problem that the contents of key functional components such as ferulic acid, cinnamaldehyde, gentiobioside and the like in the products in the prior art are to be further improved. The technical scheme has outstanding industrialization advantages, combines cost and feasibility, and has definite clinical value and industrial prospect.

Inventors

• MEI YONG
• YANG XUAN
• SU CHONG
• WANG WENJUAN
• ZHANG CHAOBO
• YUAN KAICHAO
• QIAO ZHIWEN
• CHEN LI

Assignees

• 重庆希尔安药业有限公司

Dates

Publication Date

20260512

Application Date

20260306

Claims (10)

1. 1. A traditional Chinese medicine composition granule is characterized by being prepared from 580-640 parts by weight of astragalus membranaceus, 350-400 parts by weight of fried semen lepidii, 350-400 parts by weight of ligusticum wallichii, 200-260 parts by weight of cassia twig processed by glycerol, 200-260 parts by weight of salted rhizoma alismatis, 130-160 parts by weight of platycodon grandiflorum and 60-90 parts by weight of Chinese dates.
2. 2. The granule of claim 1, wherein the glycerol-processed ramulus Cinnamomi is prepared by slicing ramulus Cinnamomi, adding glycerol solution, stirring, and oven drying until water content is less than or equal to 5%.
3. 3. The traditional Chinese medicine composition particles according to claim 2, wherein the solute mass percentage of the glycerol solution is 1-3%.
4. 4. The granule of a Chinese medicinal composition according to claim 3, wherein the temperature of the oven is 50-60 ℃.
5. 5. The traditional Chinese medicine composition particles according to claim 4, wherein the mass ratio of the twig of cinnamon to the glycerol solution is 100:10-15.
6. 6. The method for preparing the particles of the Chinese medicinal composition according to any one of claims 1 to 5, comprising the following steps sequentially carried out: s1, preparing an extract, namely firstly decocting and extracting cassia twig processed by szechuan lovage rhizome and glycerol in water to obtain a first filtrate and szechuan lovage rhizome-cassia twig mixed medicine residues, mixing the szechuan lovage rhizome-cassia twig mixed medicine residues with astragalus, fried semen lepidii, salted rhizoma alismatis, platycodon grandiflorum and Chinese dates, and then decocting and extracting in water to obtain a second filtrate; S2, preparing the composition granules, namely preparing the traditional Chinese medicine composition granules by granulating the dry paste through a wet method.
7. 7. The method for preparing the Chinese medicinal composition particles according to claim 6, wherein in S1, the cassia twig processed by the Ligusticum wallichii and the glycerol is decocted with water to extract, the feed-liquid ratio is 1 kg:10-14L, the decoction is carried out for 1-2h, and the medicinal materials are soaked for 1-2h before the decoction is carried out.
8. 8. The preparation method of the traditional Chinese medicine composition particles according to claim 7, wherein in S1, the ligusticum wallichii-cassia twig mixed dregs, astragalus mongholicus, fried semen lepidii, salted rhizoma alismatis, platycodon grandiflorum and Chinese dates are mixed, and then water decoction is carried out for extraction, wherein the feed liquid ratio is 1 kg:10-14L, and the decoction is carried out for 3 times, 1-2 hours each time.
9. 9. The method of claim 6, wherein in S2, the crushed dry extract is mixed with filler to obtain a total mixture, the total mixture is moistened with ethanol solution, and the mixture is subjected to swing granulation and boiling drying, and then subjected to granulation, mixing and packaging to obtain the finished product.
10. 10. Use of a granule of a Chinese medicinal composition according to any one of claims 1-5 for the preparation of a medicament for the treatment of chronic pulmonary heart disease.

Description

Traditional Chinese medicine composition particles and industrialized preparation method thereof Technical Field The invention relates to the technical field of pharmaceutical preparations, in particular to a traditional Chinese medicine composition granule and an industrialized preparation method thereof. Background Chronic pulmonary heart disease (Chronic Pulmonary HEART DISEASE, CPHD, abbreviated as "pulmonary heart disease") is a clinically common severe chronic disease whose pathogenesis is mainly pulmonary tissue, thoracic or pulmonary arterial system lesions, which cause pulmonary arterial hypertension, and then accompanies or progresses to right heart failure. The disease is well developed in middle-aged and elderly people, and the prevalence rate is obviously increased along with the age, so that the life quality of patients is seriously affected, and the life health of the patients is greatly threatened. In clinical diagnosis and treatment of pulmonary heart disease, the disease process is generally divided into an acute exacerbation period and a chronic remission period, wherein the remission period is used as a key period of long-term disease management, and the treatment effect directly determines the incidence frequency of acute exacerbation, the heart function deterioration speed and the long-term survival rate of patients, so that the development of an accurate treatment scheme for the remission period of pulmonary heart disease has important clinical value. The traditional Chinese medicine accumulates abundant practical experience in the treatment of pulmonary heart disease, and along with the development of modern pharmaceutical technology, the precision and industrialization of traditional Chinese medicine compound become research hotspots. In the prior art, related patents disclose a medicament for treating pulmonary heart disease, for example, the patent of the invention with the publication number of CN114010707B is entitled, which discloses a pharmaceutical composition for treating pulmonary heart disease, the composition comprises 24 parts of astragalus mongholicus, 15 parts of semen lepidii, 9 parts of fructus psoraleae, 15 parts of rhizoma ligustici wallichii with wine, 9 parts of rhizoma alismatis with salt, 6 parts of platycodon grandiflorum and 3 parts of jujube, wherein the semen lepidii is selected from the group consisting of semen lepidii with salt, the fructus psoraleae with salt, the rhizoma ligustici wallichii with wine and the rhizoma alismatis with salt. The prescription is prepared into oral preparations such as a pharmaceutical active ingredient and granules by water decoction or ethanol reflux extraction process of astragalus and ligusticum wallichii, clinical application shows that the oral preparations can effectively improve the right heart failure symptom in the remission stage of the chronic pulmonary heart disease, improve the blood oxygen partial pressure of patients, reduce the plasma fibrinogen content and the blood viscosity, have definite curative effects on lung and kidney qi deficiency symptoms, successfully solve the problems of high cost, fuzzy symptoms and difficult measurement of the curative effects of the traditional Chinese medicine, and provide a simplified and targeted definite treatment scheme for clinic. In order to further optimize the treatment effect of the traditional Chinese medicine for pulmonary heart disease, intensive researches have been conducted on the basis of the prior art, and related improvements are described in the prior patent application (application number: CN202511424584X, invention name: a pharmaceutical composition, and preparation method and application thereof). The prior patent is improved relative to the prior art in that the basic source and the processing method of the pepperweed seed in the pharmaceutical composition are optimized, the stir-fried pepperweed seed is selected to replace the original pepperweed seed, the processing specification of the szechuan lovage rhizome is adjusted, the raw szechuan lovage rhizome is adopted for compatibility, and meanwhile cassia twig is used to replace the malaytea scurfpea fruit in the original formula. Through the optimization of the formula, the traditional Chinese medicine composition shows more ideal comprehensive efficacy in the aspect of treating pulmonary heart disease, and provides a new technical direction for treating diseases. However, in the practical process of industrially preparing the optimized traditional Chinese medicine composition into granules, the content of key functional components such as ferulic acid, cinnamaldehyde, gentiobioside and the like in the granule product obtained by the existing preparation process still does not reach an ideal level, and the content of the components is directly related to the curative effect of the medicine, and the further improvement of the curative effect is limited due to the insufficient content of the components